ArtemiC is developed by MGC Pharmaceuticals d.o.o.

What development phase is ArtemiC in?

ArtemiC is FDA-approved (marketed).

Last reviewed 2026-04-22 · How we verify

ArtemiC

MGC Pharmaceuticals d.o.o · FDA-approved active Small molecule

ArtemiC is a cannabis-based pharmaceutical product that delivers cannabinoids for therapeutic effect.

At a glance

Generic name	ArtemiC
Sponsor	MGC Pharmaceuticals d.o.o
Drug class	Cannabis-derived pharmaceutical
Modality	Small molecule
Phase	FDA-approved

Mechanism of action

ArtemiC is a standardized cannabis extract product developed by MGC Pharmaceuticals. The exact mechanism depends on the cannabinoid profile and target indication, but cannabis-derived products typically work through endocannabinoid system modulation via CB1 and CB2 receptors. The specific formulation and mechanism for ArtemiC have not been widely disclosed in public literature.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ArtemiC CI brief — competitive landscape report
ArtemiC updates RSS · CI watch RSS
MGC Pharmaceuticals d.o.o portfolio CI